Ведение больных внебольничной пневмонией в амбулаторных условиях


DOI: https://dx.doi.org/10.18565/pharmateca.2020.10.8-18

А.И. Синопальников

Российская медицинская академия непрерывного профессионального образования, Москва, Россия
Пневмония остается серьезной проблемой общественного здравоохранения в связи с неприемлемо высокой заболеваемостью и смертностью. К числу вопросов, требующих решения, следует прежде всего отнести трудности в установлении первоначального клинического диагноза пневмонии, стратификацию риска неблагоприятного исхода заболевания, оптимизацию выбора эмпирической антибиотикотерапии, относительную нехватку новых антибиотиков и важность знания местных особенностей микробиологической чувствительности пневмотропных микроорганизмов. В статье обсуждается проблема ведения взрослых больных внебольничной пневмонией (ВП). Представлены сведения об эпидемиологии, диагностике, стратификации больных ВП по степени риска неблагоприятного исхода заболевания с целью определения пациентов этой категории, которые могли бы получать амбулаторное лечение без ущерба конечной эффективности и безопасности, а также антибактериальной терапии больных ВП в амбулаторных условиях, в т.ч. с применением новых антибиотиков.
Ключевые слова: внебольничная пневмония, амбулаторное лечение, антибиотикотерпия, вакцинация

Литература


1. Niederman M.S., Bass J.B. Jr., Campbell G.D., et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis. 1993;148:1418–26.


2. Pasteur L. Note on the new disease caused by the saliva of a child who died of rabies. C R Acad Sci. 1881;92:159–65. Doi: 10.1016/S2352-3018(15)00108-3.


3. Sternberg G.M. The pneumonia-coccus of Friedlander (Micrococcus Pasteuri, Sternberg). Am J Med Sci. 1885;90:106–23.


4. Fraenkel A. Weitere Beitrage zur Lehre von den Mikrococcen der genuinen fibrinosen Pneumonie


5. Osler W. The principles and practice of medicine. New York: D. Appleton and Company; 1901.


6. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death 2013 a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;385:117–71. Doi: 10.1016/S0140-6736(14)61682-2.


7. Metlay J.P., Waterer G.W., Long A.C., et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200:e45–e67. Doi: 10.1016/S0140-6736(14)61682-2.


8. Zweigner J., Meyer E., Gastmeier P., Schwab F. Rate of antibiotic prescriptions in German outpatient care – are the guidelines followed or are they still exceeded? GMS Hyg. Infect Control. 2018;13:Doc04. Doi:10.3205/dgkh000310.


9. Socie´te´ Francaise de Me´decine Ge´ne´rale. Observatoire de la Me´decine Ge´ne´ral. Donne´es en consultation pour: Pneumophatie Aigue. URL: http://omg.sfmg.org/content/donnees/donnees.php. (Accessed 28 October 2018).


10. Lim W.S., Baudouin S.V., George R.C., et al., Pneumonia Guidelines Committee of the BTS Standards of Care Committee. BTS guidelines for the management of community-acquired pneumonia in adults: update 2009. Thorax. 2009;64(Suppl. 3);iii1–55.


11. Almirall J., Serra-Prat M., Bolıbar I., Balasso V. Risk factors for community-acquired pneumonia in adults: a systematic review of observational studies. Respir. 2017;94:299–311. Doi: 10.1159/000479089.


12. Liapikou A., Cilloniz C., Torres A. Drugs that increase the risk of community-acquired pneumonia: a narrative review. Expert Opin Drug Saf. 2018;17:991–1003. Doi: 10.1080/14740338.2018.1519545.


13. Trotter C.L., Stuart J.M., George G., et al. Increasing hospital admissions for pneumonia, England. Emerg Infect Dis. 2008;14:727–33. Doi: 10.3201/eid1405.071011.


14. Almirall J., Bolibar I., Vidal J., et al. Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir. J 2000;15:757–63. Doi: 10.1034/j.1399-3003.2000.15d21.x.


15. Fine M.J., Auble T.E., Yealy D.M., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243–50. Doi: 10.1056/NEJM199701233360402.


16. Lim W.S., van der Eerden M.M., Laing R., et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377–82. Doi:10.1136/thorax.58.5.377.


17. Raut M., Schein J., Mody S., et al. Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US. Curr Med Res Opin. 2009;25:2151–57. Doi: 10.1185/03007990903102743.


18. Van Vugt S.F., Broekhuizen B.D., Lammens C., et al. Use of serum C-reactive protein and procalcitonin concentrations in addition to symptoms and signs to predict pneumonia in patients presenting to primary care with acute cough: diagnostic study. BMJ. 2013;346:f2450. Doi: 10.1136/bmj.f2450.


19. Smith S.M., Fahey T., Smucny J., Becker L.A. Antibiotics for acute bronchitis. Cochrane Database Syst Rev. 2014;3:CD000245. Doi: 10.1002/14651858.CD000245.pub3.


20. Schuetz P., Muller B., Christ-Crain M., et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev. 2012;9:CD007498. Doi: 10.1002/14651858.CD007498.pub2.


21. Ranzani O.T., Taniguchi L.U., Torres A. Severity scoring systems for pneumonia: current understanding and next steps. Curr Opin Pulm Med. 2018;24:227–36. Doi: 10.1097/MCP.0000000000000468.


22. Fine M.J., Auble T.E., Yealy D.M., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243–50. Doi: 10.1056/NEJM199701233360402.


23. Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl. 2):27–72.


24. Charles P.G., Wolfe R., Whitby M., et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis. 2008;47:375–84. Doi: 10.1086/589754.


25. Espana P.P., Capelastegui A., Gorordo I., et al. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med. 2006;174:1249–56. Doi: 10.1164/rccm.200602-177OC.


26. Singer M., Deutschman C.S., Seymour C.W., et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801–10. doi: 10.1001/jama.2016.0287.


27. Chalmers J.D., Singanayagam A., Akram A.R., et al. Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis. Thorax. 2010;65:878–83. doi: 10.1136/thx.2009.133280.


28. Bauer T.T., Ewig S., Marre R., Suttorp N., Welte T: CRB-65 predicts death from community-acquired pneumonia. J Intern Med. 2006;260:93–101. doi: 10.1111/j.1365-2796.2006.01657.x.


29. Kaysin A., Viera A.J. Community-acquired pneumonia: diagnosis and management. Am Fam Physician. 2016;94:698–706.


30. Corrales-Medina V.F., Musher D.M., Wells G.A., et al. Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation. 2012;125:773–81. Doi: 10.1161/CIRCULATIONAHA.111.040766.


31. Ewig S., Bauer T., Richter K., et al. Prediction of in-hospital death from community-acquired pneumonia by varying CRB-age groups. Eur Respir J. 2013;41:917–22. Doi: 10.1183/09031936.00065212.


32. Choudhury G., Chalmers J.D., Mandal P., et al. Physician judgement is a crucial adjunct to pneumonia severity scores in low-risk patients. Eur Respir J. 2011;38:643–48. doi: 10.1183/09031936.00172910.


33. Kolditz M., Ewig S., Schutte H., et al. Assessment of o xyg enation and comorbidities improves outcome prediction in patients with community-acquired pneumonia with a low CRB-65 score. J Intern Med. 2015;278:193–202.


34. Ewig S., Hoffken G., Kern W.V., et al. Management of adult c ommunity-acquired pneumonia and prevention – update 2016. Pneumologie. 2016;70:151–200. Doi: 10.1055/s-0042-101873.


35. Kolditz M., Braeken D., Ewig S., Rohde G. Severity assessment and the immediate and long-term prognosis in community-acquired pneumonia. Semin Respir Crit Care Med. 2016;37:886–96. Doi: 10.1055/s-0036-1592127.


36. Kolditz M., Ewig S. Community-acquired pneumonia in adults. Dtsch Arztebl Int. 2017;114:838–48. Doi: 10.3238/arztebl.2017.0838.


37. Musher D.M., Thorner A.R. Community-acquired pneumonia. N Engl J Med. 2014;371:1619–28. doi: 10.1056/NEJMra1312885.


38. Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl. 2):27–72.


39. Козлов Р.С., Зырянов С.К., Синопальников А.И. и др. Резолюция совета экспертов «Эмпирическая антибактериальная терапия инфекций дыхательных путей с учетом факторов риска резистентной флоры» (28.10.2017, Москва). Справочник поликлинического врача. 2018;1:6–10.


40. NICE. National Institute for Health and Care Excellence. Clinical Guideline


41. Cao B., Huang Y., She D.Y., et al. Diagnosis and treatment of communityacquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese Thoracic Society, Chinese Medical Association. Clin Respir J. 2018;12:1320–60.


42. Boyles T.H., Brink A., Calligaro G.L., et al. South African Thoracic Society; Federation of Infectious Diseases Societies of Southern Africa. South African guideline for the management of community-acquired pneumonia in adults. J Thorac Dis. 2017;9:1469–502. Doi: 10.21037/jtd.2017.05.31.


43. Correa R.A., Costa N.A., Lundgren F., et al. 2018 recommendations for the management of community acquired pneumonia. J Brasil Pneumol. 2018;44:405. Doi: 10.1590/S1806-37562018000000130.


44. Zaroff J.G., Craig T.C., Palmetto N., et al. Association of azithromycin use with cardiovascular mortality. JAMA. Network Open. 2020;3(6):e208199. doi: 10.1001/jamanetworkopen.2020.8199.


45. Иванчик Н.В., Чагарян А.Н., Сухорукова М.В. и др. Антибиотикорезистентность клинических штаммов Streptococcus pneumoniae в России: результаты многоцентрового эпидемиологического исследования «ПеГАС 2014–2017». Клиническая микробиология и антимикробная химиотерапия. 2019;21(3):230–37. [Ivanchik N.V., Chagaryan A.N.,


Sukhorukova M.V. et al. Antibiotic resistance of clinical strains of Streptococcus pneumoniae in Russia: results of a multicenter epidemiological study «PeGAS 2014–2017». Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2019;21(3):230–37. (In Russ.)].


46. Bjerre L.M., Verheij T.J., Kochen M.M. Antibiotics for community acquired pneumonia in adult outpatients. Cochrane Database Syst Rev. 2009;(4):CD002109. Doi:10.1002/14651858.CD002109.pub3.


47. Pakhale S., Mulpuru S., Verheij T.J., et al. Antibiotics for community-acquired pneumonia in adult outpatients. Cochrane Database Syst. Rev. 2014;(10):CD002109. Doi:10.1002/14651858.CD002109.pub4.


48. Postma D.F., van Werkhoven C.H., van Elden L.J.,et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med. 2015;372:1312–23. Doi: 10.1056/NEJMoa1406330.


49. Чучалин А.Г., Синопальников А.И., Козлов Р.С. и др. Внебольничная пневмония у взрослых. Клинические рекомендации (проект). 2019.


50. Козлов Р.С., Сухорукова М.В., Сивая О.В. и др. Чувствительность к антимикробным препаратам клинических штаммов Streptococcus pneumoniae, выделенных в различных регионах РФ в 2010–2013 гг. Клиническая микробиология и антимикробная химиотерапия. 2015;17(Приложение 1):31.


51. Sivaya O., Kozlov R., Sukhorukova M., et al. Long-term surveillance of antimicrobial resistance of H. influenzae in Russia: are there any changes in ten years? ECCMID 2016, Amsterdam, 9–12 April, Poster # EV0302.


52. Maimon N., Nopmaneejumruslers C., Marras T.K.Antibacterial class is not obviously important in outpatient pneumonia: a meta-analysis. Eur Respir J. 2008;31:1068–76. Doi: 10.1183/09031936.00109007.


53. Lonks J.R., Garau J., Gomez L., et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect. Dis. 2002;35:556–64. Doi: 10.1086/341978.


54. Daneman N., McGeer A., Green K., et al. Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. Clin Infect Dis. 2006;43:432–38.


55. Чучалин А.Г., Синопальников А.И., Козлов Р.С. и др. Внебольничная пневмония у взрослых. Практические рекомендации по диагностике, лечению и профилактике (пособие для врачей). Клиническая микробиология и антимикробная химиотерапия. 2010;12:186–225.


56. Woodhead M., Blasi F., Ewig S. and the ERS/ESCMID Task Force. Guidelines for the management of adult lower respiratory tract infections. Clin Microbiol Infect. 2011;17(Suppl. 6):1–59. Doi: 10.1111/j.1469-0691.2011.03672.x.


57. Niederman M.S. In the Clinic: Community-Acquired Pneumonia. Ann Intern Med. 2015;163:1–17. Doi: 10.7326/AITC201510060.


58. Athlin S., Lidman C., Lundqvist A., et al. Management of community-acquired pneumonia in immunocompetent adults: updated Swedish guidelines 2017. Infect. Dis. (Lond). 2018;50:247–72. Doi: 10.1080/23744235.2017.1399316.


59. Cilloniz C., Ewig S., Polverino E., et al. Community-acquired pneumonia in outpatients: aetiology and outcomes. Eur Respir J. 2012;40:931–38. Doi: 10.1183/09031936.00168811.


60. Fantin B., Aubert J.P., Unger P., et al. Clinical evaluation of the management of community-acquired pneumonia by general practitioners in France. Chest. 2001;120:185–92. doi: 10.1378/chest.120.1.185.


61. Minogue M.F., Coley C.M., Fine M.J., et al. Patients hospitalized after initial outpatient treatment for community-acquired pneumonia. Ann Emerg Med. 1998;31:376–80. Doi: 10.1016/s0196-0644(98)70350-6.


62. Prina E., Ranzani O.T., Torres A. Community-acquired pneumonia. Lancet. 2015;386:1097–108. doi: 10.1016/S0140-6736(15)60733-4.


63. Tansarli G.S., Mylonakisa E. Systematic review and meta-analysis of the efficacy of short-course antibiotic treatments for community-acquired pneumonia in adults. Antimicrob. Agents Chemother. 2018;62(9):e00635–18. Doi: 10.1128/AAC.00635-18.


64. López-Alcalde J., Rodriguez-Barrientos R., Redondo-Sánchez J., et al. Short-course versus long-course therapy of the same antibiotic for community-acquired pneumonia in adolescent and adult outpatients. Cochrane Database Syst Rev. 2018;9:CD009070. Doi: 10.1002/14651858.CD009070.pub2.


65. Silverman M., Povitz M., Sontrop J.M., et al. Antibiotic prescribing for nonbacterial acute upper respiratory infections in elderly persons. Ann Intern Med. 2017;166:765–74. Doi: 10.7326/M16-1131.


66. McDonagh M.S., Peterson K., Winthrop K., et al. Interventions to reduce inappropriate prescribing of antibiotics for acute respiratory tract infections: summary and update of a systematic review. J Int Med Res. 2018;46:3337–57. Doi: 10.1177/0300060518782519.


67. Froes F., Pereira J.G., Povoa P. Outpatient management of community-acquired pneumonia. Curr Opin Pulm Med. 2019;25:249–56. Doi: 10.1097/MCP.0000000000000558.


68. U.S. Food and Drug Administration. FDA approves new antibiotic to treat community-acquired bacterial pneumonia. URL: www.fda.gov/news-events/pressannouncements/fda-approves-new-antibiotic-treat-community-acquiredbacterial-pneumonia.


69. Rodvold K.A. Introduction: lefamulin and pharmacokinetic/ pharmacodynamic rationale to support the dose selection of lefamulin. J Antimicrob Chemother. 2019;74(Suppl 3):iii2–4. Doi: 10.1093/jac/dkz084.


70. File T.M., Goldberg L., Das A., et al. Efficacy and safety of intravenous-to-oral lefamulin, a pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia: the phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial. Clin Infect Dis. 2019;69:1856–67. Doi: 10.1093/cid/ciz090.


71. Alexander E., Goldberg L., Das A.F., et al. Oral lefamulin vs moxifloxacin for early clinical response among adults with community-acquired bacterial pneumonia: the LEAP 2 randomized clinical trial. JAMA.


72. Nabriva Therapeutics. Nabriva Therapeutics receives U.S. FDA approval of Xenleta™ (lefamulin) to treat community-acquired bacterial pneumonia (CABP). URL: https://investors.nabriva.com/news-releases/news-release-details/nabriva-therapeutics-receives-us-fda-approval-xenleta.


73. Malani P.N. Lefamulin – a new antibiotic for community-acquired pneumonia. JAMA.


74. Teng F., Liu X., Guo S.B., et al. Community-acquired bacterial co-infection predicts severity and mortality in influenza-associated pneumonia admitted patients. J Infect Chemother. 2019;25:129–36. Doi: 10.1016/j.jiac.2018.10.014.


75. Cantan B., Luyt C.E., Martin-Loeches I. Influenza Infections and Emergent Viral Infections in Intensive Care Unit. Semin Respir Crit Care Med. 2019;40:488–97. Doi: 10.1055/s-0039-1693497.


76. Bonten M.J., Huijts S.M., Bolkenbaas M., et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372:1114–25. Doi: 10.1056/NEJMoa1408544.


77. Frenck R.W. Jr., Gurtman A., Rubino J., et al. Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults. Clin Vaccine Immunol. 2012;19:1296–303. Doi: 10.1128/CVI.00176-12.


78. Schwarz T.F., Flamaing J., Rumke H.C., et al. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years. Vaccine. 2011;29:5195–202. Doi: 10.1016/j.vaccine.2011.05.031.


79. Ofori-Anyinam O., Leroux-Roels G., Drame M., et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults ≥50years of age: Results from a phase III, randomized, non-inferiority trial. Vaccine. 2017;35:6321–28. Doi: 10.1016/j.vaccine.2017.09.012.


80. Centers for Disease Control and Prevention (CDC). Recommendations of the Advisory Committee on Immunization Practices (ACIP). URL: https://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf.


81. Козлов Р.С., Авдеев С.Н., Брико Н.И. и др. Вакцинопрофилактика пневмококковых инфекций у взрослых. Резолюция совета экспертов (Москва, 16 декабря 2017 г.). Клиническая микробиология и антимикробная химиотерапия. 2018;20:5–8.


82. Matanock A., Lee G., Gierke R., et al. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices. Morb Mortal Wkly Rep. 2019;68:1069–75. Doi: 10.15585/mmwr.mm6846a5.


83. Hedlund J., Kalin M., Ortqvist A. Recurrence of pneumonia in middle-aged and elderly adults after hospital-treated pneumonia: aetiology and predisposing conditions. Scand J Infect. Dis. 1997;29:387–92. Doi: 10.3109/00365549709011836.


Об авторах / Для корреспонденции


Автор для связи: А.И. Синопальников, д.м.н., профессор, зав. кафедрой пульмонологии, Российская медицинская академия непрерывного профессионального образования, Москва, Россия; e-mail: aisyn@list.ru, ORCID: https://orcid.org/0000-0002-1990-2042 
Адрес: 125993, Россия, Москва, Баррикадная ул., 2/1, стр.1


Бионика Медиа